Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03318562 · ClinicalTrials.gov registry record · Phase 2
A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC
A Phase 2 study, sponsored by Effector Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT03318562: Clinical Trial Phase 2 study, sponsored by Effector Therapeutics.
NCT03318562 is a Phase 2 study that was terminated before completion, run by Effector Therapeutics. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03318562, a Phase 2 study, was terminated before completion, sponsored by Effector Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study will evaluate the pharmacodynamic (PD), safety, antitumor activity, and PK of eFT508 in female subjects who have pathologically documented, radiographically measurable, metastatic or locally advanced and unresectable TNBC and have received prior cancer therapy regimen for metastatic disease, and in male and female subjects who have histologically or cytologically confirmed advanced HCC not amenable to surgical resection and have failed systemic therapy.
Primary Outcome
Biomarkers of antitumor immune activation in pre- and on treatment tumor biopsies and peripheral blood cells
Interventions
- DRUG eFT508
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-11-21 |
| Est. Completion | 2019-01-22 |
| Phase | Phase 2 |
Why NCT03318562 stopped before completion
NCT03318562 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which eFT508 is the first listed.
NCT03318562 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03318562 about?
NCT03318562 is a clinical study titled "A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC". This study will evaluate the pharmacodynamic (PD), safety, antitumor activity, and PK of eFT508 in female subjects who have pathologically documented, radiographically measurable, metastatic or locally advanced and unresectable TNBC and have received prior cancer therapy regimen for metastatic disea...
What is the current status of trial NCT03318562?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2017-11-21. Estimated completion is 2019-01-22.
What interventions are being tested in trial NCT03318562?
The interventions under investigation include: eFT508 (DRUG).
Who is sponsoring clinical trial NCT03318562?
This trial is sponsored by Effector Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03318562's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI